Muscle-Based Gene Therapy and Tissue Engineering

2001 ◽  
Vol 11 (1-3) ◽  
pp. 10 ◽  
Author(s):  
Dalip Pelinkovic ◽  
Joon Yung Lee ◽  
Nobuo Adachi ◽  
Johnny Huard
Keyword(s):  
Tissue Engineering ◽  
Gene Therapy

Polymeric Delivery of Proteins and Plasmid DNA for Tissue Engineering and Gene Therapy

2001 ◽  
Vol 11 (1-3) ◽  
pp. 12 ◽  
Author(s):  
Thomas P. Richardson ◽  
William L. Murphy ◽  
David J. Mooney
Keyword(s):  
Tissue Engineering ◽  
Gene Therapy ◽  
Plasmid Dna ◽  
Polymeric Delivery

Bone tissue engineering and repair by gene therapy

10.2741/2724 ◽  
2008 ◽  
Vol 13 (13) ◽  
pp. 833 ◽  
Author(s):  
Volker, M. Betz
Keyword(s):  
Tissue Engineering ◽  
Gene Therapy ◽  
Bone Tissue Engineering ◽  
Bone Tissue

Mesenchymal Stem Cells for Bone Gene Therapy and Tissue Engineering

2002 ◽  
Vol 8 (21) ◽  
pp. 1917-1928 ◽  
Author(s):  
G. Pelled ◽  
G. Turgeman ◽  
H. Aslan ◽  
Z. Gazit ◽  
D. Gazit
Keyword(s):  
Tissue Engineering ◽  
Stem Cells ◽  
Gene Therapy ◽  
Mesenchymal Stem Cells

Gene Therapy and Tissue Engineering Based on Muscle-Derived Stem Cells

2007 ◽  
pp. 20-1-20-14
Author(s):  
Yong Li ◽  
Johnny Huard ◽  
Hairong Peng ◽  
Baohong Cao
Keyword(s):  
Tissue Engineering ◽  
Stem Cells ◽  
Gene Therapy

scholarly journals Decision Support Tools for Regenerative Medicine: Systematic Review (Preprint)

2018 ◽  
Author(s):  
Ching Lam ◽  
Edward Meinert ◽  
Abrar Alturkistani ◽  
Alison R. Carter ◽  
Jeffrey Karp ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Gene Therapy ◽  
Decision Support ◽  
Regenerative Medicine ◽  
Product Development ◽  
Cost Effective ◽  
Decision Support Tools ◽  
Cell Therapies ◽  
Allogeneic Cell Therapy ◽  
Support Tools

BACKGROUND Decisional tools have demonstrated their importance in informing manufacturing and commercial decisions in the monoclonal antibody domain. Recent approved therapies in regenerative medicine have shown great clinical benefits to patients. OBJECTIVE The objective of this review was to investigate what decisional tools are available and what issues and gaps have been raised for their use in regenerative medicine. METHODS We systematically searched MEDLINE to identify articles on decision support tools relevant to tissue engineering, and cell and gene therapy, with the aim of identifying gaps for future decisional tool development. We included published studies in English including a description of decisional tools in regenerative medicines. We extracted data using a predesigned Excel table and assessed the data both quantitatively and qualitatively. RESULTS We identified 9 articles addressing key decisions in manufacturing and product development challenges in cell therapies. The decision objectives, parameters, assumptions, and solution methods were analyzed in detail. We found that all decisional tools focused on cell therapies, and 6 of the 9 reviews focused on allogeneic cell therapy products. We identified no available tools on tissue-engineering and gene therapy products. These studies addressed key decisions in manufacturing and product development challenges in cell therapies, such as choice of technology, through modeling. CONCLUSIONS Our review identified a limited number of decisional tools. While the monoclonal antibodies and biologics decisional tool domain has been well developed and has shown great importance in driving more cost-effective manufacturing processes and better investment decisions, there is a lot to be learned in the regenerative medicine domain. There is ample space for expansion, especially with regard to autologous cell therapies, tissue engineering, and gene therapies. To consider the problem more comprehensively, the full needle-to-needle process should be modeled and evaluated.

Sign in / Sign up

Export Citation Format

Share Document